Eli Lilly's GLP-1 pill has been approved by the U.S. Food and Drug Administration, opening the next phase of the weight loss drug market. The drug, orforglipron, was licensed from Japanese drugmaker Chugai in 2018 for $50 million. Despite not producing as much weight loss as Lilly's best-selling shot Zepbound, this raises questions about its popularity. The company's CEO, Dave Ricks, called it a "big moment" as it offers an option that is more accessible and easier to incorporate into daily routines. The pill, Foundayo, will start shipping from direct-to-consumer platform LillyDirect and be available at pharmacies and telehealth platforms shortly after. Analysts predict FoundayO sales will reach $14.79 billion by 2030. In the US, Lilly will compete with Novo's Wegovy pill, which has seen early demand higher than expected.